Welcome. Coding uidelines Coding Guidelines Coding. Coding Guidelines Coding Guidelines. Contact Us. Edition #1 March 2018
|
|
- Josephine Hawkins
- 6 years ago
- Views:
Transcription
1 Coding Guidelines Coding Guidelines uidelines Coding Guidelines Coding Coding Coding Guidelines Guidelines Coding uidelines Coding Guidelines Coding Coding Chemotherapy Guidelines and Radiation Coding Therapy Guidelines Categories Edition #1 March 2018 Welcome These Coding Guidelines are designed to provide you with a quick-view of Chemotherapy and Radiation Therapy codes and corresponding descriptions and categories (listed by CPT/HCPCS). We encourage you to keep this tool handy, and hope that it will help to save you some time during the course of your workday. If you have any questions about these codes, please contact us as indicated below. Working together, we can improve health outcomes for your Today s Options patients! Contact Us Y0067_PR_TO_ChemoCodng_0218 WellCare 2018 We hope you find this coding information to be helpful. If you have any questions or need additional support, please contact your Provider Relations Representative or visit our Provider Resource Center at
2 Authorization Chemotherapy/Radiation Categories by CPT/HCPCS* CPT/HCPCS MODIFIER DESCRIPTION PPO/HMO Place po breast cath for rad Radiation Therapy Place breast rad tube/caths Radiation Therapy Ins mark thor for rt perq Radiation Therapy Insertion of infusion pump Chemotherapy Drugs Revision of infusion pump Chemotherapy Drugs Removal of infusion pump Chemotherapy Drugs Insertion catheter artery Chemotherapy Drugs Insertion of cannula(s) Chemotherapy Drugs Ins mark abd/pel for rt perq Radiation Therapy Insert tun ip cath perc Chemotherapy Drugs Insert tun ip cath w/port Chemotherapy Drugs Instll rx agnt into rnal tub Chemotherapy Drugs Treatment of bladder lesion Chemotherapy Drugs Transperi needle place pros Radiation Therapy Place rt device/marker pros Radiation Therapy Place needles pelvic for rt Radiation Therapy Insert uteri tandem/ovoids Radiation Therapy Ins vag brachytx device Radiation Therapy Insert heyman uteri capsule Radiation Therapy Implt brain chemotx add-on Chemotherapy Drugs TC Echograp trans r pros study Radiation Therapy Echograp trans r pros study Radiation Therapy TC Echo guidance radiotherapy Radiation Therapy Echo guidance radiotherapy Radiation Therapy Radiation therapy planning Radiation Therapy Radiation therapy planning Radiation Therapy Radiation therapy planning Radiation Therapy TC Set radiation therapy field Radiation Therapy Set radiation therapy field Radiation Therapy TC Set radiation therapy field Radiation Therapy Set radiation therapy field Radiation Therapy TC Set radiation therapy field Radiation Therapy Set radiation therapy field Radiation Therapy TC Respirator motion mgmt simul Radiation Therapy Respirator motion mgmt simul Radiation Therapy TC 3-d radiotherapy plan Radiation Therapy d radiotherapy plan Radiation Therapy TC Radiation therapy planning Radiation Therapy Radiation therapy planning Radiation Therapy TC Radiation therapy dose plan Radiation Therapy Radiation therapy dose plan Radiation Therapy TC Radiotherapy dose plan imrt Radiation Therapy Radiotherapy dose plan imrt Radiation Therapy TC Telethx isodose plan simple Radiation Therapy *Note: Codes are subject to change per policy updates. Today s Options PPO/HMO 2 TC = Technical Component
3 77306 Telethx isodose plan simple Radiation Therapy TC Telethx isodose plan cplx Radiation Therapy Telethx isodose plan cplx Radiation Therapy TC Brachytx isodose plan simple Radiation Therapy Brachytx isodose plan simple Radiation Therapy TC Brachytx isodose intermed Radiation Therapy Brachytx isodose intermed Radiation Therapy TC Brachytx isodose complex Radiation Therapy Brachytx isodose complex Radiation Therapy TC Special teletx port plan Radiation Therapy Special teletx port plan Radiation Therapy TC Special radiation dosimetry Radiation Therapy Special radiation dosimetry Radiation Therapy TC Radiation treatment aid(s) Radiation Therapy Radiation treatment aid(s) Radiation Therapy TC Radiation treatment aid(s) Radiation Therapy Radiation treatment aid(s) Radiation Therapy TC Radiation treatment aid(s) Radiation Therapy Radiation treatment aid(s) Radiation Therapy Radiation physics consult Radiation Therapy TC Design mlc device for imrt Radiation Therapy Design mlc device for imrt Radiation Therapy Radiation physics consult Radiation Therapy Srs multisource Radiation Therapy Srs linear based Radiation Therapy Sbrt delivery Radiation Therapy TC External radiation dosimetry Radiation Therapy External radiation dosimetry Radiation Therapy Radiation treatment delivery Radiation Therapy Radiology port film(s) Radiation Therapy Neutron beam tx simple Radiation Therapy Neutron beam tx complex Radiation Therapy Io rad tx delivery by x-ray Radiation Therapy Io rad tx deliver by elctrns Radiation Therapy Radiation tx management x5 Radiation Therapy Radiation therapy management Radiation Therapy Stereotactic radiation trmt Radiation Therapy Sbrt management Radiation Therapy Io radiation tx management Radiation Therapy TC Special radiation treatment Radiation Therapy Special radiation treatment Radiation Therapy TC Radiation therapy management Radiation Therapy Radiation therapy management Radiation Therapy Proton trmt simple w/o comp Radiation Therapy Proton trmt simple w/comp Radiation Therapy Proton trmt intermediate Radiation Therapy Proton treatment complex Radiation Therapy TC Hyperthermia treatment Radiation Therapy Hyperthermia treatment Radiation Therapy TC Hyperthermia treatment Radiation Therapy Today s Options PPO/HMO 3 TC = Technical Component
4 77605 Hyperthermia treatment Radiation Therapy TC Hyperthermia treatment Radiation Therapy Hyperthermia treatment Radiation Therapy TC Hyperthermia treatment Radiation Therapy Hyperthermia treatment Radiation Therapy TC Hyperthermia treatment Radiation Therapy Hyperthermia treatment Radiation Therapy TC Infuse radioactive materials Radiation Therapy Infuse radioactive materials Radiation Therapy TC Apply intrcav radiat simple Radiation Therapy Apply intrcav radiat simple Radiation Therapy TC Apply intrcav radiat interm Radiation Therapy Apply intrcav radiat interm Radiation Therapy TC Apply intrcav radiat compl Radiation Therapy Apply intrcav radiat compl Radiation Therapy TC Hdr rdncl skn surf brachytx Radiation Therapy Hdr rdncl skn surf brachytx Radiation Therapy TC Hdr rdncl skn surf brachytx Radiation Therapy Hdr rdncl skn surf brachytx Radiation Therapy TC Hdr rdncl ntrstl/icav brchtx Radiation Therapy Hdr rdncl ntrstl/icav brchtx Radiation Therapy TC Hdr rdncl ntrstl/icav brchtx Radiation Therapy Hdr rdncl ntrstl/icav brchtx Radiation Therapy TC Hdr rdncl ntrstl/icav brchtx Radiation Therapy Hdr rdncl ntrstl/icav brchtx Radiation Therapy TC Apply interstit radiat compl Radiation Therapy Apply interstit radiat compl Radiation Therapy TC Apply surface radiation Radiation Therapy Apply surface radiation Radiation Therapy TC Radiation handling Radiation Therapy Radiation handling Radiation Therapy TC Radium/radioisotope therapy Radiation Therapy Radium/radioisotope therapy Radiation Therapy Spin/brain pump refil & main Chemotherapy Drugs Spin/brain pump refil & main Chemotherapy Drugs Ther/proph/diag iv inf init Chemotherapy Drugs Ther/proph/diag iv inf addon Chemotherapy Drugs Tx/proph/dg addl seq iv inf Chemotherapy Drugs Ther/diag concurrent inf Chemotherapy Drugs Sc ther infusion up to 1 hr Chemotherapy Drugs Sc ther infusion addl hr Chemotherapy Drugs Sc ther infusion reset pump Chemotherapy Drugs Tx/pro/dx inj same drug adon Chemotherapy Drugs Chemo anti-neopl sq/im Chemotherapy Drugs Chemo hormon antineopl sq/im Chemotherapy Drugs Chemo intralesional up to 7 Chemotherapy Drugs Chemo intralesional over 7 Chemotherapy Drugs Chemo iv push sngl drug Chemotherapy Drugs Chemo iv push addl drug Chemotherapy Drugs Chemo iv infusion 1 hr Chemotherapy Drugs Today s Options PPO/HMO 4 TC = Technical Component
5 96415 Chemo iv infusion addl hr Chemotherapy Drugs Chemo prolong infuse w/pump Chemotherapy Drugs Chemo iv infus each addl seq Chemotherapy Drugs Chemo ia push tecnique Chemotherapy Drugs Chemo ia infusion up to 1 hr Chemotherapy Drugs Chemo ia infuse each addl hr Chemotherapy Drugs Chemotherapy infusion method Chemotherapy Drugs Chemotherapy intracavitary Chemotherapy Drugs Chemotx admn prtl cavity Chemotherapy Drugs Chemotherapy into cns Chemotherapy Drugs Refill/maint portable pump Chemotherapy Drugs Refill/maint pump/resvr syst Chemotherapy Drugs Irrig drug delivery device Chemotherapy Drugs Chemotherapy injection Chemotherapy Drugs Chemotherapy unspecified Chemotherapy Drugs C1714 Catheter, transluminal atherectomy, directional Radiation Therapy C1715 Brachytherapy needle Radiation Therapy C1716 Brachytherapy source, non-stranded, gold-198, per source Radiation Therapy C1717 Brachytherapy source, non-stranded, high dose rate iridium-192, per source Radiation Therapy C1719 Brachytherapy source, non-stranded, non-high dose rate iridium-192, per source Radiation Therapy C1728 Catheter, brachytherapy seed administration Radiation Therapy C2616 Brachytherapy source, non-stranded, yttrium-90, per source Radiation Therapy C2634 Brachytherapy source, non-stranded, high activity, iodine-125, greater than... Radiation Therapy C2635 Brachytherapy source, non-stranded, high activity, paladium-103, greater th... Radiation Therapy C2636 Brachytherapy linear source, non-stranded, paladium-103, per 1 mm Radiation Therapy C2637 Brachytherapy source, non-stranded, ytterbium-169, per source Radiation Therapy C2638 Brachytherapy source, stranded, iodine-125, per source Radiation Therapy C2639 Brachytherapy source, non-stranded, iodine-125, per source Radiation Therapy C2640 Brachytherapy source, stranded, palladium-103, per source Radiation Therapy C2641 Brachytherapy source, non-stranded, palladium-103, per source Radiation Therapy C2642 Brachytherapy source, stranded, cesium-131, per source Radiation Therapy C2643 Brachytherapy source, non-stranded, cesium-131, per source Radiation Therapy C2698 Brachytherapy source, stranded, not otherwise specified, per source Radiation Therapy C2699 Brachytherapy source, non-stranded, not otherwise specified, per source Radiation Therapy C9725 Placement of endorectal intracavitary applicator for high intensity brachyt... Radiation Therapy C9726 Placement and removal (if performed) of applicator into breast for intraope... Radiation Therapy C9728 Placement of interstitial device(s) for radiation therapy/surgery guidance... Radiation Therapy G0339 Robot lin-radsurg com, first Radiation Therapy G0340 Robt lin-radsurg fractx 2-5 Radiation Therapy Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with G0498 continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion Chemotherapy Drugs G6001 Echo guidance radiotherapy Radiation Therapy G6002 Stereoscopic x-ray guidance Radiation Therapy G6003 Radiation treatment delivery Radiation Therapy G6004 Radiation treatment delivery Radiation Therapy G6005 Radiation treatment delivery Radiation Therapy G6006 Radiation treatment delivery Radiation Therapy Today s Options PPO/HMO 5 TC = Technical Component
6 G6007 Radiation treatment delivery Radiation Therapy G6008 Radiation treatment delivery Radiation Therapy G6009 Radiation treatment delivery Radiation Therapy G6010 Radiation treatment delivery Radiation Therapy G6011 Radiation treatment delivery Radiation Therapy G6012 Radiation treatment delivery Radiation Therapy G6013 Radiation treatment delivery Radiation Therapy G6014 Radiation treatment delivery Radiation Therapy G6015 Radiation tx delivery imrt Radiation Therapy G6016 Delivery comp imrt Radiation Therapy G6017 Intrafraction track motion Radiation Therapy J0897 Denosumab injection Chemotherapy Drugs J1459 Inj ivig privigen 500 mg Chemotherapy Drugs J1557 Gammaplex injection Chemotherapy Drugs J1561 Gamunex-c/gammaked Chemotherapy Drugs J1566 Immune globulin, powder Chemotherapy Drugs J1568 Octagam injection Chemotherapy Drugs J1569 Gammagard liquid injection Chemotherapy Drugs J1572 Flebogamma injection Chemotherapy Drugs J8498 Antiemetic rectal/supp nos Chemotherapy Drugs J8501 Oral aprepitant Chemotherapy Drugs J8510 Oral busulfan Chemotherapy Drugs J8520 Capecitabine, oral, 150 mg Chemotherapy Drugs J8521 Capecitabine, oral, 500 mg Chemotherapy Drugs J8530 Cyclophosphamide oral 25 mg Chemotherapy Drugs J8540 Oral dexamethasone Chemotherapy Drugs J8560 Etoposide oral 50 mg Chemotherapy Drugs J8562 Oral fludarabine phosphate Chemotherapy Drugs J8597 Antiemetic drug oral nos Chemotherapy Drugs J8600 Melphalan oral 2 mg Chemotherapy Drugs J8610 Methotrexate oral 2.5 mg Chemotherapy Drugs J8650 Nabilone oral Chemotherapy Drugs J8655 Netupitant palonosetron oral Chemotherapy Drugs J8655 Netupitant 300 mg and palonosetron 0.5 mg Chemotherapy Drugs J8670 Rolapitant, oral, 1 mg Chemotherapy Drugs J8700 Temozolomide Chemotherapy Drugs J8705 Topotecan oral Chemotherapy Drugs J8999 Oral prescription drug chemo Chemotherapy Drugs J9000 Doxorubicin hcl injection Chemotherapy Drugs J9015 Aldesleukin injection Chemotherapy Drugs J9017 Arsenic trioxide injection Chemotherapy Drugs J9019 Erwinaze injection Chemotherapy Drugs J9020 Asparaginase, nos Chemotherapy Drugs J9022 Inj, atezolizumab,10 mg Chemotherapy Drugs J9023 Injection, avelumab, 10 mg Chemotherapy Drugs J9025 Azacitidine injection Chemotherapy Drugs J9027 Clofarabine injection Chemotherapy Drugs J9031 Bcg live intravesical vac Chemotherapy Drugs J9032 Injection, belinostat, 10mg Chemotherapy Drugs J9032 Injection, belinostat, 10 mg Chemotherapy Drugs Today s Options PPO/HMO 6 TC = Technical Component
7 J9033 Bendamustine injection Chemotherapy Drugs J9034 Injection, bendamustine hcl (bendeka), 1 mg Chemotherapy Drugs J9035 Bevacizumab injection Chemotherapy Drugs J9039 Injection, blinatumomab Chemotherapy Drugs J9039 Injection, blinatumomab, 1 microgram Chemotherapy Drugs J9040 Bleomycin sulfate injection Chemotherapy Drugs J9041 Bortezomib injection Chemotherapy Drugs J9042 Brentuximab vedotin inj Chemotherapy Drugs J9043 Cabazitaxel injection Chemotherapy Drugs J9045 Carboplatin injection Chemotherapy Drugs J9047 Injection, carfilzomib, 1 mg Chemotherapy Drugs J9050 Carmustine injection Chemotherapy Drugs J9055 Cetuximab injection Chemotherapy Drugs J9060 Cisplatin 10 mg injection Chemotherapy Drugs J9065 Inj cladribine per 1 mg Chemotherapy Drugs J9070 Cyclophosphamide 100 mg inj Chemotherapy Drugs J9098 Cytarabine liposome inj Chemotherapy Drugs J9100 Cytarabine hcl 100 mg inj Chemotherapy Drugs J9120 Dactinomycin injection Chemotherapy Drugs J9130 Dacarbazine 100 mg inj Chemotherapy Drugs J9145 Injection, daratumumab, 10 mg Chemotherapy Drugs J9150 Daunorubicin injection Chemotherapy Drugs J9151 Daunorubicin citrate inj Chemotherapy Drugs J9155 Degarelix injection Chemotherapy Drugs J9160 Denileukin diftitox inj Chemotherapy Drugs J9165 Diethylstilbestrol injection Chemotherapy Drugs J9171 Docetaxel injection Chemotherapy Drugs J9175 Elliotts b solution per ml Chemotherapy Drugs J9176 Injection, elotuzumab, 1 mg Chemotherapy Drugs J9178 Inj, epirubicin hcl, 2 mg Chemotherapy Drugs J9179 Eribulin mesylate injection Chemotherapy Drugs J9181 Etoposide injection Chemotherapy Drugs J9185 Fludarabine phosphate inj Chemotherapy Drugs J9190 Fluorouracil injection Chemotherapy Drugs J9200 Floxuridine injection Chemotherapy Drugs J9201 Gemcitabine hcl injection Chemotherapy Drugs J9202 Goserelin acetate implant Chemotherapy Drugs J9203 Gemtuzumab ozogamicin 0.1 mg Chemotherapy Drugs J9205 Injection, irinotecan liposome, 1 mg Chemotherapy Drugs J9206 Irinotecan injection Chemotherapy Drugs J9207 Ixabepilone injection Chemotherapy Drugs J9208 Ifosfamide injection Chemotherapy Drugs J9209 Mesna injection Chemotherapy Drugs J9211 Idarubicin hcl injection Chemotherapy Drugs J9212 Interferon alfacon-1 inj Chemotherapy Drugs J9213 Interferon alfa-2a inj Chemotherapy Drugs J9214 Interferon alfa-2b inj Chemotherapy Drugs J9215 Interferon alfa-n3 inj Chemotherapy Drugs J9216 Interferon gamma 1-b inj Chemotherapy Drugs J9217 Leuprolide acetate suspnsion Chemotherapy Drugs Today s Options PPO/HMO 7 TC = Technical Component
8 J9218 Leuprolide acetate injeciton Chemotherapy Drugs J9219 Leuprolide acetate implant Chemotherapy Drugs J9225 Vantas implant Chemotherapy Drugs J9226 Supprelin la implant Chemotherapy Drugs J9228 Ipilimumab injection Chemotherapy Drugs J9230 Mechlorethamine hcl inj Chemotherapy Drugs J9245 Inj melphalan hydrochl 50 mg Chemotherapy Drugs J9250 Methotrexate sodium inj Chemotherapy Drugs J9260 Methotrexate sodium inj Chemotherapy Drugs J9261 Nelarabine injection Chemotherapy Drugs J9262 Inj, omacetaxine mep, 0.01mg Chemotherapy Drugs J9263 Oxaliplatin Chemotherapy Drugs J9264 Paclitaxel protein bound Chemotherapy Drugs J9266 Pegaspargase injection Chemotherapy Drugs J9267 Paclitaxel injection Chemotherapy Drugs J9268 Pentostatin injection Chemotherapy Drugs J9270 Plicamycin (mithramycin) inj Chemotherapy Drugs J9271 Inj pembrolizumab Chemotherapy Drugs J9271 Injection, pembrolizumab, 1 mg Chemotherapy Drugs J9280 Mitomycin injection Chemotherapy Drugs J9285 Inj, olaratumab, 10 mg Chemotherapy Drugs J9293 Mitoxantrone hydrochl / 5 mg Chemotherapy Drugs J9295 Injection, necitumumab, 1 mg Chemotherapy Drugs J9299 Injection, nivolumab Chemotherapy Drugs J9299 Injection, nivolumab, 1 mg Chemotherapy Drugs J9301 Obinutuzumab inj Chemotherapy Drugs J9302 Ofatumumab injection Chemotherapy Drugs J9303 Panitumumab injection Chemotherapy Drugs J9305 Pemetrexed injection Chemotherapy Drugs J9306 Injection, pertuzumab, 1 mg Chemotherapy Drugs J9307 Pralatrexate injection Chemotherapy Drugs J9308 Injection, ramucirumab Chemotherapy Drugs J9308 Injection, ramucirumab, 5 mg Chemotherapy Drugs J9310 Rituximab injection Chemotherapy Drugs J9315 Romidepsin injection Chemotherapy Drugs J9320 Streptozocin injection Chemotherapy Drugs J9325 Injection, talimogene laherparepvec, per 1 million plaque forming units Chemotherapy Drugs J9328 Temozolomide injection Chemotherapy Drugs J9330 Temsirolimus injection Chemotherapy Drugs J9340 Thiotepa injection Chemotherapy Drugs J9351 Topotecan injection Chemotherapy Drugs J9352 Injection, trabectedin, 0.1 mg Chemotherapy Drugs J9354 Inj, ado-trastuzumab emt 1mg Chemotherapy Drugs J9355 Trastuzumab injection Chemotherapy Drugs J9357 Valrubicin injection Chemotherapy Drugs J9360 Vinblastine sulfate inj Chemotherapy Drugs J9370 Vincristine sulfate 1 mg inj Chemotherapy Drugs J9371 Inj, vincristine sul lip 1mg Chemotherapy Drugs Today s Options PPO/HMO 8 TC = Technical Component
9 J9390 Vinorelbine tartrate inj Chemotherapy Drugs J9395 Injection, fulvestrant Chemotherapy Drugs J9400 Inj, ziv-aflibercept, 1mg Chemotherapy Drugs J9600 Porfimer sodium injection Chemotherapy Drugs J9999 Chemotherapy drug Chemotherapy Drugs Q0083 Chemo by other than infusion Chemotherapy Drugs Q0084 Chemotherapy by infusion Chemotherapy Drugs Q0085 Chemo by both infusion and o Chemotherapy Drugs Q0161 Chlorpromazine hcl 5mg oral Chemotherapy Drugs Q0162 Ondansetron oral Chemotherapy Drugs Q0163 Diphenhydramine hcl 50mg Chemotherapy Drugs Q0164 Prochlorperazine maleate 5mg Chemotherapy Drugs Q0166 Granisetron hcl 1 mg oral Chemotherapy Drugs Q0167 Dronabinol 2.5mg oral Chemotherapy Drugs Q0169 Promethazine hcl 12.5mg oral Chemotherapy Drugs Q0173 Trimethobenzamide hcl 250mg Chemotherapy Drugs Q0174 Thiethylperazine maleate10mg Chemotherapy Drugs Q0175 Perphenazine 4mg oral Chemotherapy Drugs Q0177 Hydroxyzine pamoate 25mg Chemotherapy Drugs Q0180 Dolasetron mesylate oral Chemotherapy Drugs Q0181 Unspecified oral anti-emetic Chemotherapy Drugs Q0477 Pwr module pt cable lvad rpl Chemotherapy Drugs Q2043 Sipuleucel-t auto cd54+ Chemotherapy Drugs Q3001 Brachytherapy radioelements Radiation Therapy Today s Options PPO/HMO 9 TC = Technical Component
Primary malignant neoplasms, not lymphatic or hematopoietic. Secondary malignant neoplasms (i.e.metastatic) Malignant neoplasm, unknown site
Supplementary Table 1. ICD-9-CM codes used to define cancer ICD-9 Diagnosis code 140.xx-172.xx 174.xx-195.xx 196.xx 198.xx 199.xx 200.xx-208.xx Description Primary malignant neoplasms, not lymphatic or
More informationVivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19
Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19 All Non-Par Provider Requests Requires Authorization Regardless of Service J0178 J0180 J0202 J0205
More informationMEDICAL NECESSITY GUIDELINE
PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationSubject: Fosnetupitant-Palonosetron (Akynzeo) IV
09-J3000-01 Original Effective Date: 06/15/18 Reviewed: 05/09/18 Revised: 01/01/19 Subject: Fosnetupitant-Palonosetron (Akynzeo) IV THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,
More informationSubject: Palonosetron Hydrochloride (Aloxi )
09-J0000-87 Original Effective Date: 02/15/09 Reviewed: 07/09/14 Revised: 03/15/18 Subject: Palonosetron Hydrochloride (Aloxi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationPart B payment for drugs in Medicare 0
Part B payment for drugs in Medicare 0 Introduction: The recent pilot proposal 1 on Part B drug payment from the Center for Medicare and Medicaid Innovation of CMS has met strong resistance 2 from the
More informationPart B payment for drugs in Medicare: Phase 1 of CMS s proposed pilot and its impact on oncology care
Part B payment for drugs in Medicare: Phase 1 of CMS s proposed pilot and its impact on oncology care Raina H. Jain, Stephen M. Schleicher, Coral L. Atoria, Peter B. Bach Executive Summary The recent pilot
More informationSubject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi )
09-J2000-60 Original Effective Date: 06/15/16 Reviewed: 04/11/18 Revised: 01/01/19 Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT
More informationCommittee Approval Date: December 12, 2014 Next Review Date: July 2015
Medication Policy Manual Policy No: dru378 Topic: Akynzeo, netupitant/palonosetron Date of Origin: December 12, 2014 Committee Approval Date: December 12, 2014 Next Review Date: July 2015 Effective Date:
More informationPart B payment for drugs in Medicare 0
Part B payment for drugs in Medicare 0 Introduction: The recent pilot proposal 1 on Part B drug payment from the Center for Medicare and Medicaid Innovation of CMS has met strong resistance 2 from the
More informationUse of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A
Supportive Care in Cancer Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A Systematic Review of the Medicare Database Romina Sosa, Shuling Li, Julia T. Molony, Jiannong
More informationCPT Service Description Effective Date
Medical Oncology Program Review Code List 2 nd Quarter 2018 This list is subject to change once per quarter. Changes will be posted to the BCBSNC website at www.bcbsnc.com by the 10th day of January, April,
More informationGuidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients
Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For
More informationCurrent and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Objectives
Current and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Susan Urba, M.D. University of Michigan Comprehensive Cancer Center Objectives Mechanisms of
More informationDME MAC Jurisdiction C Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2018 through 03/31/2018
G0333 PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); INITIAL 30-DAY SUPPLY AS A BENEFICIARY $57.000 J0133 INJECTION, ACYCLOVIR 5 MG $0.068 J0285 INJECTION, AMPHOTERICIN B 50 MG $32.987 J0287 INJECTION,
More informationDME MAC Jurisdiction B Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2019 through 03/31/2019
G0333 PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); INITIAL 30-DAY SUPPLY AS A BENEFICIARY $57.000 J0133 INJECTION, ACYCLOVIR 5 MG $0.048 J0285 INJECTION, AMPHOTERICIN B 50 MG $31.668 J0287 INJECTION,
More informationINJECTION, INOTUZUMAB OZOGAMICIN, 0.1 MG [BESPONSA ] [C CODES FOR FACILITY USE ONLY]
Commercial Medical Oncology Program Review Code List 3rd Quarter 2018 This list is subject to change once per quarter. Changes will be posted to the BCBSNC website at www.bcbsnc.com by the 10th day of
More informationDescription The following are synthetic cannabinoids requiring prior authorization: dronabinol (Marinol, Syndros ), nabilone (Cesamet )
Clinical Policy: Nabilone (Cesamet), Dronabinol (Marinol, Syndros) Reference Number: CP.CPA.242 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important
More informationJ1556 INJECTION, IMMUNE GLOBULIN (BIVIGAM) 500 MG $ J1559 INJECTION, IMMUNE GLOBULIN (HIZENTRA) 100 MG $14.364
G0333 INITIAL 30-DAY SUPPLY AS A BENEFICIARY $57.000 J0133 INJECTION, ACYCLOVIR 5 MG $0.470 J0285 INJECTION, AMPHOTERICIN B 50 MG $10.280 J0287 INJECTION, AMPHOTERICIN B LIPID COMPLEX 10 MG $21.850 J0288
More informationManagements of Chemotherpay Induded Nausea and Vomiting
REVIEW ARTICLE Managements of Chemotherpay Induded Nausea and Vomiting Department of Surgery, The Catholic University of Korea Sung Geun Kim 23 24 Sung Geun Kim Korean Journal of Clinical Oncology Summer
More informationGUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION
GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY More than half of all cancer patients experience nausea or vomiting during the course of their treatment. If nausea or vomiting becomes severe enough,
More informationGuideline Update on Antiemetics
Guideline Update on Antiemetics Clinical Practice Guideline Special Announcements Please check www.asco.org/guidelines/antiemetics for current FDA alert(s) and safety announcement(s) on antiemetics 2 Introduction
More informationWest of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting
West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial
More informationSCI. SickKids-Caribbean Initiative Enhancing Capacity for Care in Paediatric Cancer and Blood Disorders
1.0 Introduction The (SCI) is a not-for-profit collaboration between the Hospital for Sick Children (SickKids), Toronto, Canada, and seven Caribbean health care institutions across six countries that strive
More informationANTIEMETICS UTILIZATION MANAGEMENT CRITERIA
ANTIEMETICS [Akynzeo, Anzemet, Cesamet, Emend, Sancuso, Varubi, Zuplenz ] DRUG CLASS: UTILIZATION MANAGEMENT CRITERIA 5-HT 3 Receptor Antagonists 5-HT 3 Receptor Antagonist and Substance P/Neurokinin (NK
More informationExhibit B United States Patent Application 20020012663 Kind Code A1 Waksal, Harlan W. January 31, 2002 Treatment of refractory human tumors with epidermal growth factor receptor antagonists Abstract A
More informationELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY
ELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY Problem Opening PACS Images on ipads or ibooks has Been Fixed Changes have been made in PROD to enable user credentials to be passed
More informationAdult Intravenous Systemic Anticancer Therapy (SACT) Section A. SUMMARY of SCHEME QIPP Reference
CA2 Nationally standardised Dose banding for Adult Intravenous Anticancer Therapy (SACT) Scheme Name CA2: Nationally Standardised Dose Banding for Adult Intravenous Systemic Anticancer Therapy (SACT) Section
More informationPrevention and Management of chemo-and radiotherapy-induced nausea and vomiting
Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University of Heidelberg
More informationGuidelines for the Use of Anti-Emetics with Chemotherapy
Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting
More informationMASCC Guidelines for Antiemetic control: An update
MASCC / ISOO 17 th International Symposium Supportive Care in Cancer June 30 July 2, 2005 / Geneva, Switzerland MASCC Guidelines for Antiemetic control: An update Sussanne Börjeson, RN, PhD Linköping University,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Zofran, Zuplenz) Reference Number: CP.CPA.173 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this
More informationHaematology, Oncology and Palliative Care Directorate.
Anticancer Treatment for Administration on the Somerset Mobile Chemotherapy Unit The table below details the suitability of different types of anticancer treatment for administration on the Somerset Mobile
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.223 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationObjective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites.
WARDS/DEPARTMENTS By: 0 01/09/019 1 of 3 Objective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites. Scope: All Black
More informationDOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days
Last updated Oct 17, 2018 Tumour Group Protocol Number Protocol Name on NCCP website Breast 200 Trastuzumab (IV) Monotherapy 21 days 201 Trastuzumab (IV) Monotherapy 7 days 202 DOCEtaxel Monotherapy 100mg/m2
More informationAPPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer
APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer 5850/5980 University Avenue, PO Box 9700, Halifax, N.S. B3K 6R8 PEDIATRIC HEMATOLOGY/ONCOLOGY
More informationEmetogenicity level 1. Emetogenicity level 2
Emetogenicity level 1 15 mins Pre-Chemo Maxalon 10mg po During chemo and Post Chemo 3 days Maxalon10mg po 8 hourly Increase Maxalon 20mg po 8 hourly Change to Cyclizine 50mg po 8 hourly 3 days If nausea
More informationChemotherapy-induced Nausea and Vomiting: The Pharmacist s Role in Integrating Clinical Guidelines into Patient Care
Chemotherapy-induced Nausea and Vomiting: The Pharmacist s Role in Integrating Clinical Guidelines into Patient Care Presented as a Live Webinar Wednesday, April 13, 2016 12:00 p.m. 1:00 p.m. ET Tuesday,
More informationProtocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy
Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/2018 221 Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal
More informationGuideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients
Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients POGO Antineoplastic Induced Nausea and Vomiting Guideline Development Panel: L.
More informationTo help doctors give their patients the best possible care, the American
Patient Information Resources from ASCO What to Know ASCO s Guideline on Preventing Vomiting Caused by Cancer Treatment SEPTEMBER 2011 KEY MESSAGES The risk of nausea and vomiting depends on the specific
More informationProtocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249
Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin
More informationNorthern Cancer Alliance
Northern Cancer Alliance Anti-emetic Guidelines for Chemotherapy Induced Nausea and Vomiting (CINV) Adult Oncology & Haematology Document Control Document Title: Antiemetic Guidelines for CINV NESCN v2.2
More informationDrug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015
J0129 Injection, abatacept (Orencia ), 10 J0178 Injection, aflibercept (Eylea ), 1 J0256 J0257 J0585 J0586 J0587 J0588 J0597 J0641 J0717 J0800 Injection, alpha 1-proteinase inhibitor, human (Aralast NP,
More information1. Purpose Documentation Description.1 4. References 8 5. Cross-References.8 6. Development of the guideline.8
CLINICAL GUIDELINE For use in (clinical areas): For use by (staff groups): For use for (patients): Document owner: Status: Oncology/Haematology Unit (excluding Paediatrics) Oncologists, Haematologists,
More informationAD regimen, 576 adrenal steroid inhibitor. aminoglutethimide, 23 25
A 640 Index Index abiraterone acetate, 5 7 Abraxane. See albuminbound paclitaxel ABVD regimen, 57, 540 ABV regimen, 519 520 AC docetaxel regimen, 476, 478 acetaminophen busulfan and, 71 AC regimen, 475,
More informationThe following are J Code requirements
The following are J Code requirements J Codes 20610 Arthrocentesis, aspiration and/or injection; major joint or bursa (eg, shoulder, hip, knee joint, subacromial bursa) A9579 Injection, gadolinium based
More informationDrug Use Evaluation: Physician Administered Drugs (PADs)
Drug Use Research & Management Program OHA Division of Medical Assistance Programs 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Drug Use Evaluation: Physician Administered
More informationΑκτινοθεραπευτική Ογκολογία & Παθολογική Ογκολογία
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A problem focused history; A problem focused examination; Straightforward medical
More informationSURVEY SUL CONFLITTO DI INTERESSE IN ONCOLOGIA PROMOSSO DAL CIPOMO 1-31 MARZO. PARTECIPATE TUTTI nicsonet.it
SURVEY SUL CONFLITTO DI INTERESSE IN ONCOLOGIA PROMOSSO DAL CIPOMO 1-31 MARZO PARTECIPATE TUTTI www.cipomo.it; nicsonet.it LINEE GUIDA AIOM: LA TERAPIA ANTIEMETICA Fausto Roila S.C. Oncologia Medica, Terni
More informationThe AngCN Antiemetic Guidelines
The AngCN Antiemetic Guidelines Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy AngCN Document Reference: AngCN-CCG-C31 CONTENTS 1.0 Introduction
More informationAntiemesis. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version NCCN.org. Continue
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 1.2016 NCCN.org Continue Version 1.2016 03/15/16 National Comprehensive Cancer Network, Inc. 2016, All rights reserved. The NCCN
More informationChemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines
North of England Cancer Network Chemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines Adult Oncology & Haematology Quality and safety for every patient every time For more information
More informationCancer: Can we Afford the Cure? Current Trends in Oncology Treatment
Cancer: Can we Afford the Cure? Current Trends in Oncology Treatment Julie Kennerly-Shah, PharmD, MS, MHA, BCPS May 30, 2018 The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer
More informationHow ICD-10 Affects Radiation Oncology. Presented by, Lashelle Bolton CPC, COC, CPC-I, CPMA
How ICD-10 Affects Radiation Oncology Presented by, Lashelle Bolton CPC, COC, CPC-I, CPMA ICD-10 ICD-10-CM has added new challenges to the radiation oncology specialty. Approximately 220 ICD-9-CM codes
More informationVI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic
More informationCorporate Medical Policy
Antiemetic Injection Therapy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: antiemetic_injection_therapy 5/2015 3/2017 3/2018 3/2017 Description of Procedure
More informationAntiemesis. NCCN Clinical Practice Guidelines in Oncology. Antiemesis. Version Continue
Table of Contents Clinical in Oncology Version 2.2010 Continue www.nccn.org Version 2.2010, 04/07/2010 2010 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration
More informationJob title: Consultant Pharmacist/Advanced Practice Pharmacist
Title : Guidelines for the Use of Antiemetics Purpose: To provide trust-wide guidance on the safe and effective use of antiemetics for the prevention and treatment of chemotherapy and radiotherapy induced
More informationWho Should Know Radiation Oncology Coding?
Why Should We Learn Radiation Oncology Coding? Terry Wu, Ph.D. Chief Physicist Radiation Oncology Department Willis-Knighton Cancer Center Who Should Know Radiation Oncology Coding? Radiation Oncologist
More informationMedicare Part C Medical Coverage Policy
Medicare Part C Medical Coverage Policy Oral Antiemetic Medications Origination: June 17, 2009 Review Date: May 17, 2017 Next Review: May, 2019 DESCRIPTION OF PROCEDURE OR SERVICE Oral antiemetic medications
More informationAntiemesis. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version NCCN.org. Continue
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 1.2015 NCCN.org Continue Version 1.2015, 04/01/15 National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN
More informationICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced
ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced Class Medicine Name Nappi Strength Form Size Route Abiraterone Acetate ZYTIGA
More informationAdverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and
35 Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and Biologically directed therapies ) 1 1- Nausea and vomiting
More informationAntiemetic Guidelines. Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy
Antiemetic Guidelines Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy For approvals and version control see Document Management Record
More informationClinical Policy: Dolasetron (Anzemet) Reference Number: ERX.NPA.83 Effective Date:
Clinical Policy: (Anzemet) Reference Number: ERX.NPA.83 Effective Date: 09.01.18 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationTable III: 2019 Medicare Drug Fee Schedule* CY st Quarter Average Sales Price (ASP) Data Plus 6 Percent
Table III: 2019 Medicare Drug Fee Schedule* CY 2019 1st Quarter Average Sales Price (ASP) Data Plus 6 Percent *The Medicare payments allowance limits are effective Jan. 1 thru March. 31, 2019. CY 2019
More informationSupportive care session 1:
Board review in oncology pharmacy 2013 Managing Disease or Treatment Related Complication Supportive care session 1: Chemotherapy induced-nausea and vomiting Suthan Chanthawong, B. Pharm, RPh. Objectives
More informationintolerance to, contraindication to, or therapeutic failure on a minimum 3 month trial of Inflectra*
What s New Medical Pharmaceutical Policy March 2018 Updates MBP 5.0 Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda)- Updated policy Remicade (infliximab), Inflectra (infliximab-dyyb)
More informationHCPCS Code/ generic (Brand) Name J7506. J8520 capecitabine (Xeloda) 1. J8521 capecitabine. J8530 cyclophosphamide. (Cytoxan) 1
drug and administration compendia Current Price () J7506 Prednisone, oral, per 5 mg 12/1/07 $0.07 $0.19 N/A prednisone 2 J8520 capecitabine (Xeloda) 1 Capecitabine, oral, 150 mg 8/1/07 $5.79 $4.59 N/A
More informationTrust Guideline for Prevention and Control of Chemotherapy and Radiotherapy Induced Nausea and Vomiting in Adults
A Clinical Guideline For Use in: Organisation-wide By: For: Key words: Name of document author: Job title of document author: Name of document author s Line Manager: Job title of author s Line Manager:
More informationHodgkin and Non-Hodgkin Lymphoma (LYM) Post-Infusion Data
Hodgkin and Non-Hodgkin Lymphoma (LYM) Post-Infusion Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: CIBMTR Research ID: Event date: / / Visit 100 day 6 months 1 year 2 years
More informationPatient-Centered Management of Chemotherapy-Induced Nausea and Vomiting
Clear and accurate communication between patients and health care teams is the key to successfully controlling chemotherapy-induced nausea and vomiting. Roseate Spoonbill_2005. Photograph courtesy of Henry
More informationChemotherapy induced emesis: Are we doing are best? David Warr University of Toronto
Chemotherapy induced emesis: Are we doing are best? David Warr University of Toronto david.warr@uhn.on.ca Conflict of interest Merck: speakers bureau and consultant Eisai: consultant Outline What is the
More informationNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Antiemesis. Version NCCN.org. Continue
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 1.2011 NCCN.org Continue Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that
More informationCOST CONSIDERATIONS Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines!!!!!!!!!
UICCEMLCostingScenarios BackoftheEnvelope Calculations PreparedforWorkingGroupSession:19621November2014,Geneva MethodsSummary We have chosen a conservative approach, calculating cost per vial. We have
More informationClinical Tools and Resources for Self-Study and Patient Education
Clinical Tools and Resources for Self-Study and Patient Education CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING CLINICIAN'S RESOURCE GUIDE The clinical tools and resources contained herein are provided as educational
More informationClinical Policy: Nabilone (Cesamet) Reference Number: ERX.NPA.35 Effective Date:
Clinical Policy: (Cesamet) Reference Number: ERX.NPA.35 Effective Date: 09.01.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More information1 The Cancer Programs Regulation (AR 242/98) is amended by this Regulation.
Alberta Regulation 18/2005 Cancer Programs Act AMENDMENT REGULATION Filed: February 22, 2005 For information only: Made by the Minister of Health and Wellness (M.O. 9/2005) on February 17, 2005 pursuant
More informationProvider Administered Drug Program (PADP) and Physician Administered Drug VPSS List
Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List Code Drug Name Effective and/or Term Date J0129 Injection, abatacept (Orencia ), 10 mg J0178 Injection, aflibercept (Eylea
More informationHazardous Medication List
Hazardous Medication List REDUCING OCCUPATIONAL EXPOSURE TO HAZARDOUS MEDICATION FOR ALL STAFF Table of Contents Hazardous Medication List Key Points... 1 Hazardous Medication List... 2 Special Handling
More informationMDwise Self-Administered Codes for Medical
The following codes are associated with medications that can be self-administered by the patient or a caregiver. As a result, MDwise will transfer coverage of these self-administered medications exclusively
More informationOvarian Cancer. compendia TREATMENT OF
drug & compendia TREATMENT OF Ovarian Cancer With each publication, ManagedCare Oncology s drug & Compendia highlights a single medication or a group of medications that could be utilized in the management
More informationRichard J. Gralla, MD Medical Director Quality of Life Research Associates New York, NY
Oncology Consultations Improving the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) A CE-Certified Activity Featuring Consultations With Supported by an educational grant from Eisai. Dannemiller
More informationDRUG EXTRAVASATION. Vesicants. Irritants
DRUG EXTRAVASATION Vesicants Irritants Vesicants Antineoplastic drugs Amsacrine Dactinomycin Daunorubicin Docetaxel (rare) Doxorubicin Epirubicin Idarubicin Mechlorethamine Mitomycin Oxaliplatin (rare)
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Anzemet) Reference Number: CP.PMN.141 Effective Date: 09.01.06 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationSystemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients
Systemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients Pathway of Care Kent & Medway Cancer Collaborative Publication date June 2018
More informationDRUG PROPERTIES YOU NEED TO KNOW
Dr. Janet Fitzakerley Summer 2013 Med 6541 Hematopoiesis and Host Defences jfitzake@d.umn.edu www.d.umn.edu/~jfitzake Page 1 of 11 DRUG PROPERTIES YOU NEED TO KNOW 1. Mechanism of action a. chemical class
More informationDisclosure. Objectives. Objectives. Oncologic Emergency. Classification of Emergencies 1 3/2/2015
Disclosure Oncologic Emergencies and Acute Supportive Care of the Critically Ill Oncology Patient By: Kimberly Regis, Pharm.D. Broward Health Medical Center Pharmacy Resident 2014-2015 I do not have a
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Cesamet) Reference Number: CP.PMN.160 Effective Date: 11.16.16 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationTitle Developed By. Implementation Contact person(s) Review Date Group Responsible. NICaN Policy: Management of Chemotherapy Extravasation; Version 3
Title Developed By Management of Chemotherapy Extravasation NICaN Regional Pharmacy Group Version History Version 3: 2009 (See appendix 6) Version 2: January 2006 Version 1: June 2005 Consultation Period
More informationGuidelines for the Management of Extravasation (Version 5 May 2012)
Guidelines for the Management of Extravasation (Version 5 May 2012) Quality and safety for every patient every time Document Control Prepared By Chemo Nurse Group Chemo Nurse Group/ South Tees FT NECDAG
More informationRecognising and reducing the risk of chemotherapy extravasation
Recognising and reducing the risk of chemotherapy extravasation When chemotherapy drugs leak from the veins it can cause serious injury to the patient, greatly heighten their fears of undergoing future
More informationASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER
European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref.: EMEA/384641/2006 ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER The Paediatric
More informationAntiemetics: Guidelines, Interactions and more.
Antiemetics: Guidelines, Interactions and more. Chemotherapy-induced side effects -the patient s view Loss of hair The thought of coming for chemo Affects family/partner Affects work/home duties Jude Lees
More informationAcute Lymphocytic Leukemia
Acute Lymphocytic Leukemia Splenectomy (Removal of Spleen) 6-Mercaptopurine (Purinethol, 6-MP) Alemtuzumab (Campath ) Arsenic Trioxide (Trisenox ) Bendamustine (Treanda ) Bexarotene (Targretin ) Bleomycin
More information